Comparison of Famciclovir and Lamivudine in the Long-term Treatment of Hepatitis B Infection After Liver Transplantation
Overview
Affiliations
Background: Preliminary results of short-term famciclovir and lamivudine therapy in patients with hepatitis B virus (HBV) infection after liver transplantation revealed promising results. In a retrospective study the efficacy of long-term treatment with these substances was compared.
Methods: A total of 53 HBV-infected adults (48 reinfections and 7 de novo infections) received antiviral treatment. A total of 32 of these patients were treated with famciclovir 3x500 mg, 20 of them were later switched to lamivudine. Fourteen patients received lamivudine, 150 mg/day orally, as first line therapy and 7 patients after failure of famciclovir-prophylaxis. Follow-up time was 8 to 62 months (mean 35 months). Response to therapy (HBV-DNA negative) was compared using Kaplan-Meier estimates. Potential influence factors (HBV-DNA and HBeAg pretransplant, HDV coinfection, pretreatment with famciclovir and immunosuppression) on treatment response were analyzed by log. Rank test (univariate); then a multivariate analysis (Cox multiple stepwise regression model) was applied.
Results: A total of 19 and 76% of the patients treated with famciclovir and lamivudine resp. became HBV-DNA negative; 0 and 24% HBsAg negative. Lamivudine was also effective as second line therapy. In a multivariate analysis of all 73 treatment courses, lamivudine treatment and HDV-coinfection were significant factors for better treatment response; regarding only the lamivudine group, negative HBeAg pretransplant was significant. Viral breakthrough after prolonged treatment occurred in 55% (lamivudine) to 80% (famciclovir) of treatment courses but was only accompanied by mild hepatitis.
Conclusions: Lamivudine and famciclovir are potent drugs for the treatment of HBV-infection after liver transplantation. The antiviral capacity of lamivudine is superior even after pretreatment with famciclovir but after prolonged treatment viral breakthrough is often observed.
Rossi M, Mennini G, Lai Q, Ginanni Corradini S, Drudi F, Pugliese F J Ultrasound. 2013; 10(1):28-45.
PMID: 23396075 PMC: 3478701. DOI: 10.1016/j.jus.2007.02.006.
Jiang L, Yan L World J Gastroenterol. 2010; 16(20):2468-75.
PMID: 20503446 PMC: 2877176. DOI: 10.3748/wjg.v16.i20.2468.
Schreibman I, Schiff E Ann Clin Microbiol Antimicrob. 2006; 5:8.
PMID: 16600049 PMC: 1459192. DOI: 10.1186/1476-0711-5-8.
Hepatitis B virus infection in liver transplant candidates and recipients.
Yachimski P, Chung R MedGenMed. 2005; 7(2):20.
PMID: 16369399 PMC: 1681606.
Treatment of follicular non-Hodgkin's lymphoma.
Maloney D Curr Hematol Rep. 2004; 4(1):39-45.
PMID: 15610658 DOI: 10.1007/s11901-005-0025-1.